دورية أكاديمية
Molecular predictors for decitabine efficacy in meningiomas - a pilot study.
| العنوان: | Molecular predictors for decitabine efficacy in meningiomas - a pilot study. |
|---|---|
| المؤلفون: | Spille DC; Department of Neurosurgery, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, North Rhine-Westphalia, Germany., Thomas C; Institute of Neuropathology, University Hospital Münster, Münster, North Rhine-Westphalia, Germany., Wagner A; Institute of Neuropathology, University Hospital Münster, Münster, North Rhine-Westphalia, Germany., Grauer OM; Department of Neurology, University of Münster, Münster, North Rhine-Westphalia, Germany., Canisius J; Department of Neurosurgery, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, North Rhine-Westphalia, Germany., Bunk EC; Department of Neurosurgery, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, North Rhine-Westphalia, Germany., Stummer W; Department of Neurosurgery, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, North Rhine-Westphalia, Germany., Eich HT; Department of Radiation Oncology, University Hospital Münster, Münster, North Rhine-Westphalia, Germany., Paulus W; Institute of Neuropathology, University Hospital Münster, Münster, North Rhine-Westphalia, Germany., Senner V; Institute of Neuropathology, University Hospital Münster, Münster, North Rhine-Westphalia, Germany., Brokinkel B; Department of Neurosurgery, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, North Rhine-Westphalia, Germany. benjamin.brokinkel@mail.de.; Institute of Neuropathology, University Hospital Münster, Münster, North Rhine-Westphalia, Germany. benjamin.brokinkel@mail.de. |
| المصدر: | Journal of neuro-oncology [J Neurooncol] 2023 Aug; Vol. 164 (1), pp. 97-105. Date of Electronic Publication: 2023 Jul 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: United States NLM ID: 8309335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7373 (Electronic) Linking ISSN: 0167594X NLM ISO Abbreviation: J Neurooncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2005- : New York : Springer Original Publication: Boston : M. Nijhoff, 1983- |
| مواضيع طبية MeSH: | Meningioma*/drug therapy , Meningioma*/genetics , Meningeal Neoplasms*/drug therapy , Meningeal Neoplasms*/genetics, Humans ; Decitabine/pharmacology ; Decitabine/therapeutic use ; Azacitidine/pharmacology ; Azacitidine/therapeutic use ; DNA (Cytosine-5-)-Methyltransferases/genetics ; DNA (Cytosine-5-)-Methyltransferases/metabolism ; Pilot Projects ; Ki-67 Antigen/metabolism ; Enzyme Inhibitors/pharmacology ; DNA Methylation ; Cell Line, Tumor ; Myelin and Lymphocyte-Associated Proteolipid Proteins/genetics ; Myelin and Lymphocyte-Associated Proteolipid Proteins/metabolism |
| مستخلص: | Purpose: Effective chemotherapeutical agents for the treatment of meningiomas are still lacking. Previous in-vitro analyses revealed efficacy of decitabine (DCT), a DNA methyltransferase (DNMT) inhibitor established in the treatment of leukemia, in a yet undefined subgroup of meningiomas. Methods: Effects of DCT on proliferation and viability was analyzed in primary meningioma cells by immunofluorescence and MTT assays, and cases were classified as drug responders and non-responders. Molecular preconditions for efficacy were analyzed using immunofluorescence for Ki67, DNMT1, and five oncogenes (TRIM58, FAM84B, ELOVL2, MAL2, LMO3) previously found to be differentially methylated after DCT exposition, as well as by genome-wide DNA methylation analyses. Results: Efficacy of DCT (10µM) was found in eight (62%) of 13 meningioma cell lines 48 h after drug exposition (p < .05). DCT significantly reduced DNMT1 expression in all but two cell lines, and median ΔDNMT1 reduction 48 h after drug exposition was lower in DCT-resistant (-11.1%) than in DCT-sensitive (-50.5%, p = .030) cells. Rates of cell lines responsive to DCT exposition distinctly decreased to 25% after 72 h. No significant correlation of the patients´ age, sex, histological subtype, location of the paternal tumor, expression of Ki67, DNMT1 or the analyzed oncogenes with treatment response was found (p > .05, each). DCT efficacy was further independent of the methylation class and global DNA methylation of the paternal tumor. Conclusion: Early effects of DCT in meningiomas are strongly related with DNMT1 expression, while clinical, histological, and molecular predictors for efficacy are sparse. Kinetics of drug efficacy might indicate necessity of repeated exposition and encourage further analyses. (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, Preusser M, Minniti G, Lund-Johansen M, Lefranc F, Houdart E, Sallabanda K, Le Rhun E, Nieuwenhuizen D, Tabatabai G, Soffietti R, Weller M (2021) EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 23:1821–1834. https://doi.org/10.1093/neuonc/noab150. (PMID: 10.1093/neuonc/noab150341817338563316) Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39. (PMID: 10.1136/jnnp.20.1.2213406590497230) Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, Chukwueke U, Forst DA, Arrillaga-Romany IC, Dietrich J, Corbin Z, Moliterno J, Baehring J, White M, Lou KW, Larson J, de Sauvage MA, Evancic K, Mora J, Nayyar N, Loeffler J, Oh K, Shih HA, Curry WT, Cahill DP, Barker FG, Gerstner ER, Santagata S (2022) Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun 13:1325. https://doi.org/10.1038/s41467-022-29052-7. (PMID: 10.1038/s41467-022-29052-7352893298921328) Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers. https://clinicaltrials.gov/ct2/show/NCT03173950 . Accessed 11 November 2022. He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, Lian XY, Xu ZJ, Qian J, Lin J (2017) Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Oncotarget 8:41498–41507. https://doi.org/10.18632/oncotarget.17241. (PMID: 10.18632/oncotarget.17241284895685522197) Hagemann S, Heil O, Lyko F, Brueckner B (2011) Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS ONE 6:e17388. https://doi.org/10.1371/journal.pone.0017388. (PMID: 10.1371/journal.pone.0017388214082213049766) Chabot GG, Rivard GE, Momparler RL (1983) Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2’-deoxycytidine in rabbits and dogs. Cancer Res 43:592–597. (PMID: 6184151) Boulagnon-Rombi C, Fleury C, Fichel C, Lefour S, Marchal Bressenot A, Gauchotte G (2017) Immunohistochemical Approach to the Differential diagnosis of Meningiomas and their mimics. J Neuropathol Exp Neurol 76:289–298. https://doi.org/10.1093/jnen/nlx008. (PMID: 10.1093/jnen/nlx00828340171) Lall RR, Lall RR, Smith TR, Lee KH, Mao Q, Kalapurakal JA, Marymont MH, Chandler JP (2014) Delayed malignant transformation of petroclival meningioma to chondrosarcoma after stereotactic radiosurgery. J Clin Neurosci 21:1225–1228. https://doi.org/10.1016/j.jocn.2013.11.015. (PMID: 10.1016/j.jocn.2013.11.01524491582) Hamm CA, Xie H, Costa FF, Vanin EF, Seftor EA, Sredni ST, Bischof J, Wang D, Bonaldo MF, Hendrix MJ, Soares MB (2009) Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2’-deoxycytidine results in increased tumorigenicity. PLoS ONE 4:e8340. https://doi.org/10.1371/journal.pone.0008340. (PMID: 10.1371/journal.pone.0008340200198182790612) Samal S, Patnaik A, Sahu F, Purkait S (2020) Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice. Folia Neuropathol 58:133–142. https://doi.org/10.5114/fn.2020.96970. (PMID: 10.5114/fn.2020.9697032729292) Wang B, Cui Z, Zhong Z, Sun Y, Yang GY, Sun Q, Bian L (2016) The role and regulatory mechanism of IL-1beta on the methylation of the NF2 gene in benign meningiomas and leptomeninges. Mol Carcinog 55:2268–2277. https://doi.org/10.1002/mc.22467. (PMID: 10.1002/mc.2246726840621) Stogbauer L, Thomas C, Wagner A, Warneke N, Bunk EC, Grauer O, Canisius J, Paulus W, Stummer W, Senner V, Brokinkel B (2020) Efficacy of decitabine in malignant meningioma cells: relation to promoter demethylation of distinct tumor suppressor and oncogenes and independence from TERT. J Neurosurg 1–10. https://doi.org/10.3171/2020.7.JNS193097. Canisius J, Wagner A, Bunk EC, Spille DC, Stogbauer L, Grauer O, Hess K, Thomas C, Paulus W, Stummer W, Senner V, Brokinkel B (2022) Expression of decitabine-targeted oncogenes in meningiomas in vivo. Neurosurg Rev 45:2767–2775. https://doi.org/10.1007/s10143-022-01789-1. (PMID: 10.1007/s10143-022-01789-1354459109349086) Tatman PD, Wroblewski TH, Fringuello AR, Scherer SR, Foreman WB, Damek DM, Lillehei KO, Jensen RL, Youssef AS, Ormond DR, Graner MW (2022) Targeting DNA methyl transferases with decitabine in cultured meningiomas. World Neurosurg 162:e99–e119. https://doi.org/10.1016/j.wneu.2022.02.108. (PMID: 10.1016/j.wneu.2022.02.10835248772) Sahm F, Brastianos PK, Claus EB, Mawrin C, Perry A, Santagata S, von Deimlig A (2021) Meningioma. In: Brat DJ, Ellison DW, Figarella-Branger D, Hawkins CE, Louis DN, Ng H, Perry A, Pfister S, Reifenberger G, Soffietti R, von Deimlig A, Wesseling P (eds) Central Nervous System Tumours 5th Edition, 6 edn. International Agency for Research on Cancer, Lyon (France), pp 284–297. Bunk EC, Wagner A, Stummer W, Senner V, Brokinkel B (2021) 5-ALA kinetics in meningiomas: analysis of tumor fluorescence and PpIX metabolism in vitro and comparative analyses with high-grade gliomas. J Neurooncol 152:37–46. https://doi.org/10.1007/s11060-020-03680-9. (PMID: 10.1007/s11060-020-03680-933389565) Hardy SJ, Christodoulides M, Weller RO, Heckels JE (2000) Interactions of Neisseria meningitidis with cells of the human meninges. Mol Microbiol 36:817–829. https://doi.org/10.1046/j.1365-2958.2000.01923.x. (PMID: 10.1046/j.1365-2958.2000.01923.x10844670) Ganetsky A (2012) The role of decitabine for the treatment of acute myeloid leukemia. Ann Pharmacother 46:1511–1517. https://doi.org/10.1345/aph.1R151. (PMID: 10.1345/aph.1R15123115225) Krishnadas DK, Bao L, Bai F, Chencheri SC, Lucas K (2014) Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. Tumour Biol 35:5753–5762. https://doi.org/10.1007/s13277-014-1764-9. (PMID: 10.1007/s13277-014-1764-924584817) Sagransky MJ, Deng AC, Magro CM (2013) Primary cutaneous langerhans cell sarcoma: a report of four cases and review of the literature. Am J Dermatopathol 35:196–204. https://doi.org/10.1097/DAD.0b013e3182661c0b. (PMID: 10.1097/DAD.0b013e3182661c0b23051626) Higuchi T, Han Q, Miyake K, Oshiro H, Sugisawa N, Tan Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM (2020) Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. Biochem Biophys Res Commun 523:135–139. https://doi.org/10.1016/j.bbrc.2019.12.024. (PMID: 10.1016/j.bbrc.2019.12.02431839218) Al-Romaih K, Sadikovic B, Yoshimoto M, Wang Y, Zielenska M, Squire JA (2008) Decitabine-induced demethylation of 5’ CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 10:471–480. https://doi.org/10.1593/neo.08174. (PMID: 10.1593/neo.08174184729642373908) Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK (2005) Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 36:416–425. https://doi.org/10.1016/j.humpath.2005.02.006. (PMID: 10.1016/j.humpath.2005.02.00615892004) Furtjes G, Kochling M, Peetz-Dienhart S, Wagner A, Hess K, Hasselblatt M, Senner V, Stummer W, Paulus W, Brokinkel B (2016) hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas. J Neurooncol 130:79–87. https://doi.org/10.1007/s11060-016-2226-6. (PMID: 10.1007/s11060-016-2226-627465278) Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA (2013) Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 4:1729–1736. https://doi.org/10.18632/oncotarget.1412. (PMID: 10.18632/oncotarget.1412240778263858559) Park JW, Sahm F, Steffl B, Arrillaga-Romany I, Cahill D, Monje M, Herold-Mende C, Wick W, Turcan S (2021) TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro Oncol 23:76–87. https://doi.org/10.1093/neuonc/noaa207. (PMID: 10.1093/neuonc/noaa20732882013) Chan HSC, Ng HK, Chan AK, Cheng SH, Chow C, Wong N, Wong GKC (2021) Establishment and characterization of meningioma patient-derived organoid. J Clin Neurosci 94:192–199. https://doi.org/10.1016/j.jocn.2021.10.035. (PMID: 10.1016/j.jocn.2021.10.03534863437) Choudhury A, Magill ST, Eaton CD, Prager BC, Chen WC, Cady MA, Seo K, Lucas CG, Casey-Clyde TJ, Vasudevan HN, Liu SJ, Villanueva-Meyer JE, Lam TC, Pu JK, Li LF, Leung GK, Swaney DL, Zhang MY, Chan JW, Qiu Z, Martin MV, Susko MS, Braunstein SE, Bush NAO, Schulte JD, Butowski N, Sneed PK, Berger MS, Krogan NJ, Perry A, Phillips JJ, Solomon DA, Costello JF, McDermott MW, Rich JN, Raleigh DR (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54:649–659. https://doi.org/10.1038/s41588-022-01061-8. (PMID: 10.1038/s41588-022-01061-8355345629374001) Yamazaki S, Ohka F, Hirano M, Shiraki Y, Motomura K, Tanahashi K, Tsujiuchi T, Motomura A, Aoki K, Shinjo K, Murofushi Y, Kitano Y, Maeda S, Kato A, Shimizu H, Yamaguchi J, Adilijiang A, Wakabayashi T, Saito R, Enomoto A, Kondo Y, Natsume A (2021) Newly established patient-derived organoid model of intracranial meningioma. Neuro Oncol 23:1936–1948. https://doi.org/10.1093/neuonc/noab155. (PMID: 10.1093/neuonc/noab155342141698563327) |
| فهرسة مساهمة: | Keywords: 5-Aza-2′-desoxycytidin; Chemotherapy; Decitabine; Meningiomas; Molecular |
| المشرفين على المادة: | 776B62CQ27 (Decitabine) M801H13NRU (Azacitidine) EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases) 0 (Ki-67 Antigen) 0 (Enzyme Inhibitors) 0 (MAL2 protein, human) 0 (Myelin and Lymphocyte-Associated Proteolipid Proteins) |
| تواريخ الأحداث: | Date Created: 20230721 Date Completed: 20230829 Latest Revision: 20230829 |
| رمز التحديث: | 20230830 |
| DOI: | 10.1007/s11060-023-04379-3 |
| PMID: | 37477823 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1573-7373 |
|---|---|
| DOI: | 10.1007/s11060-023-04379-3 |